Could transplanted islets free diabetics from insulin?

NCT ID NCT01909245

Ongoing Disease control Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether transplanting insulin-producing islet cells from donors into the liver can help people with type 1 diabetes control blood sugar without insulin shots. Ten participants receive strong anti-rejection drugs to protect the new cells. Researchers will track blood sugar, insulin use, and quality of life for five years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Allogenic human islet cells, anti-thymocyte globulin, alemtuzumab, and gastrin 17
What this could lead to: If successful, this could help people with type 1 diabetes achieve better blood sugar control without needing insulin injections, though lifelong anti-rejection drugs are still required.
What could go wrong: This is a small, early-phase trial with only 10 participants, so results may not apply to everyone. The anti-rejection drugs have serious side effects, including increased infection risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypoglycemia type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 1 DIABETES MELLITUS

Contacts and locations

Locations

City of Hope Medical Center

Duarte, California, 91010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.